Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02783105
Other study ID # 6224
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date November 20, 2016
Est. completion date December 18, 2019

Study information

Verified date November 2016
Source University Hospital, Strasbourg, France
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Paroxysmal sympathetic hyperactivity (PSH) is a frequent symptom after traumatic brain injury and concerns up to 30% of severely brain-injured patients. PSH is due to unbalanced autonomic nervous system activity, resulting in sympathetic surges causing hypertension, tachycardia, sweating and hypertonia. The affected patients suffer more pain, more cardiovascular distress, more infections and prolonged rehabilitation and mechanical ventilation; additionally it could lead to a worse outcome. Classical music was shown to reduce autonomic nervous system imbalance in healthy people and in many medical diseases. It could be a means to dampen sympathetic surges for brain-injured patients presenting with PSH, as well. Our study aims at demonstrating that early musical intervention, started with the weaning of sedation, can reduce both the prevalence and the severity of paroxysmal sympathetic hyperactivity in traumatic brain-injured patients.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date December 18, 2019
Est. primary completion date January 4, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Severe traumatic brain injury (either initial Glasgow Coma Scale < 8 or intracranial pressure > 20mmHg for more than 20 min) - National health service coverage - Informed consent signed by next of kin Exclusion Criteria: - Non-traumatic brain injury - Conditions interfering with measures: bilateral fixed pupils, temporal bone fracture including acoustic channel, eye trauma, previous eye surgery, otorrhagia, hypoacusis, - Preexisting autonomic nervous system imbalance: severe diabetes, arrhythmias, pace maker, implantable defibrillator, cardiac transplantation - Respiratory rate < 9/min - Patient subject to guardianship or wardship - Pregnant or breastfeeding woman - Current participation in another biomedical research protocol

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Musical intervention

Control
Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham

Locations

Country Name City State
France Service d'Anesthésie Réanimation- Hôpital de Hautepierre Strasbourg

Sponsors (5)

Lead Sponsor Collaborator
University Hospital, Strasbourg, France Association française des traumatisés crâniens d'Alsace, Association strasbourgeoise des médecins et infirmiers en anesthésie réanimation, Fondation Apicil, MDMS

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Paroxysmal Sympathetic Hyperactivity Assessment Measure [PSH-AM] (ranging from 0 to 29) The PSH-AM combines the sum of Clinical Features Scale [CFS] (from 0 to 18) and the Diagnostic Likelihood tool [DLT] (from 0 to 11) from desedation (Day 0) to Day 21.
Secondary Area under the Clinical Features Scale curve from Day 0 to Day 21.
Secondary Mean Analgesia Nociception Index from Day 0 to Day 21.
Secondary Neurological Pupil Index from Day 0 to Day 21.
Secondary Pain (Critical-Care Pain Observation Tool) from Day 0 to Day 21.
Secondary Neurological outcome (Wessex Head Injury Matrix) from Day 0 to Day 21.
Secondary PSH-AM Six and twelve months
Secondary Disability Rating Scale Six and twelve months
See also
  Status Clinical Trial Phase
Recruiting NCT05343988 - Percutaneous Neurostimulation to Treat Paroxysmal Sympathetic Hyperactivity in Children N/A
Completed NCT06090812 - Initial Volume Status in Patients With Acute Brain Injury is Associated With Neurological Prognosis
Enrolling by invitation NCT06354673 - Stellate Ganglion Block Combined With Dexmedetomidine or Subanesthetic Ketamine Infusion for Treatment of Neurostorm. N/A